Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pulmonology
Volume 2013, Article ID 831871, 4 pages
http://dx.doi.org/10.1155/2013/831871
Case Report

Metastatic Bladder Cancer Presenting with Persistent Hematuria in Young Man with Cystic Fibrosis

1Department of Medicine, The University of Calgary, Calgary, AB, Canada T2N 4N1
2Department of Microbiology and Infectious Diseases, The University of Calgary, Calgary, AB, Canada T2N 4N1
3Department of Oncology, The University of Calgary, Calgary, AB, Canada T2N 4N1
43330 Hospital Drive NW, Health Sciences Center, The University of Calgary, Calgary, AB, Canada T2N 4N1

Received 11 March 2013; Accepted 15 April 2013

Academic Editors: D. Franzen, E. Gabbay, and K. M. Nugent

Copyright © 2013 Premal Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Foundation CCF, Canadian Cystic Fibrosis Foundation Patient Data Registry Report, Toronto, Canada, 2007.
  2. M. D. Parkins, V. M. Parkins, J. C. Rendall, and S. Elborn, “Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population,” Therapeutic Advances in Respiratory Disease, vol. 5, no. 2, pp. 105–119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. P. Neglia, S. C. FitzSimmons, P. Maisonneuve et al., “The risk of cancer among patients with cystic fibrosis,” New England Journal of Medicine, vol. 332, no. 8, pp. 494–499, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. M. H. Schoni, P. Maisonneuve, F. Schoni-Affolter, and A. B. Lowenfels, “Cancer risk in patients with cystic fibrosis: the European data. CF/CSG Group,” Journal of the Royal Society of Medicine, vol. 89, supplement 27, pp. 38–43, 1996. View at Google Scholar
  5. P. Maisonneuve, S. C. FitzSimmons, J. P. Neglia, P. W. Campbell, and A. B. Lowenfels, “Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study,” Journal of the National Cancer Institute, vol. 95, no. 5, pp. 381–387, 2003. View at Google Scholar · View at Scopus
  6. M. Johannesson, J. Askling, S. M. Montgomery, A. Ekbom, and S. Bahmanyar, “Cancer risk among patients with cystic fibrosis and their first-degree relatives,” International Journal of Cancer, vol. 125, no. 12, pp. 2953–2956, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Murta-Nascimento, B. J. Schmitz-Dräger, M. P. Zeegers et al., “Epidemiology of urinary bladder cancer: from tumor development to patient's death,” World Journal of Urology, vol. 25, no. 3, pp. 285–295, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. C. F. Lynch and M. B. Cohen, “Urinary system,” Cancer, vol. 75, no. 1, supplement, pp. 316–329, 1995. View at Google Scholar · View at Scopus
  9. Y. C. Wen, J. Y. Kuo, K. K. Chen et al., “Urothelial carcinoma of the urinary bladder in young adults—Clinical experience at Taipei Veterans General Hospital,” Journal of the Chinese Medical Association, vol. 68, no. 6, pp. 272–275, 2005. View at Google Scholar · View at Scopus
  10. M. R. Perez-Brayfield, D. Caplan, J. M. Gatti, E. A. Smith, and A. J. Kirsch, “Metabolic risk factors for stone formation in patients with cystic fibrosis,” Journal of Urology, vol. 167, no. 2, pp. 480–484, 2002. View at Google Scholar · View at Scopus
  11. M. Terribile, M. Capuano, G. Cangiano et al., “Factors increasing the risk for stone formation in adult patients with cystic fibrosis,” Nephrology Dialysis Transplantation, vol. 21, no. 7, pp. 1870–1875, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Yu, T. Zhu, Z. Wang et al., “A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer,” Clinical Cancer Research, vol. 13, no. 24, pp. 7296–7304, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Touw, “Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis,” Pharmacy World and Science, vol. 20, no. 4, pp. 149–160, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Rey, J. M. Tréluyer, and G. Pons, “Drug disposition in cystic fibrosis,” Clinical Pharmacokinetics, vol. 35, no. 4, pp. 313–329, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Von der Maase, S. W. Hansen, J. T. Roberts et al., “Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3068–3077, 2000. View at Google Scholar · View at Scopus
  16. B. Casserly and W. Donat, “Stabilization of lung function and clinical symptoms in a patient with Cystic Fibrosis (CF) after institution of infliximab: a monoclonal antibody that binds tumor necrosis factor alpha,” Lung, vol. 187, no. 3, pp. 149–152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Vincenzi, B. Bizzarri, A. Ghiselli, N. de' Angelis, F. Fornaroli, and G. L. de' Angelis, “Cystic fibrosis and Crohn's disease: successful treatment and long term remission with infliximab,” World Journal of Gastroenterology, vol. 16, no. 15, pp. 1924–1927, 2010. View at Publisher · View at Google Scholar · View at Scopus